title: Serotonin dysregulation in Fragile X Syndrome: implications for treatment.
abstract: Fragile X Syndrome (FXS) is a trinucleotide repeat disorder that results in the silencing of the Fragile X Mental Retardation 1 gene (FMR1), leading to a lack of the FMR1 protein (FMRP). FMRP is an mRNA-binding protein that regulates the translation of hundreds of mRNAs important for synaptic plasticity. Several of these pathways have been identified and have guided the development of targeted treatments for FXS. Here we present evidence that serotonin is dysregulated in FXS and treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline may be beneficial for individuals with FXS, particularly in early childhood.
authors.affiliation: UC Davis School of Medicine, Sacramento, CA, USA;
authors.forename: Alicia C
authors.initials: AC
authors.lastname: Hanson
authors.affiliation: UC Davis MIND Institute and Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA.
authors.forename: Randi J
authors.initials: RJ
authors.lastname: Hagerman
keywords: Fragile X Syndrome; fragile X mental retardation protein; selective serotonin reuptake inhibitors; sertraline